AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

592.019

+4.8130.82%

Number of Gainers:14

Number of Losers:17

Number of Flat:14

PE:- -

High:594.788

Open:587.853

Low:587.853

Close:587.206

Volume:60.43M

Turnover:151.64M

Market Cap:81.38B

Float Cap:78.30B

Loading ...

Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%

MT Newswires Live

Clinuvel H1 net profit after tax AUD 10.4 million -26%

BRIEF-Dimerix Loss For Half-Year Attributable A$16 Million

BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million

Clinuvel Pharmaceuticals Ltd - Hy Revenues a$36.9 Mln

THOMSON REUTERS

Dimerix Ltd - Loss for Half-Year Attributable a$16 Mln

THOMSON REUTERS

Monash IVF Group H1 Adjusted EBIT AUD 17.478 Million

THOMSON REUTERS

Monash IVF Group H1 Adjusted Ebitda AUD 30.16 Million

THOMSON REUTERS

Monash IVF Group Ltd - Expecting FY26 Underlying Group Npat of a$20 Mln

THOMSON REUTERS

Did Soft Half-Year Results and CEO Transition Just Shift CSL's (ASX:CSL) Investment Narrative?

Simply Wall St.

Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

MT Newswires Live

Optical Communication Stocks Jump. Lumentum Soars Nearly 10%; Coherent up 8%; Lumen Technologies up over 7%; Fabrinet up 6%

Tiger Newspress

BRIEF-Immuron Reports Hy26 Results And Strategic Reset

Mesoblast Ltd expected to post a loss of 7 cents a share - Earnings Preview

Immuron Ltd: Taken a Strategic Decision to Pursue Partnerships to Fund Progress of Travelan and Imm-529 Clinical Programs

THOMSON REUTERS

Immuron Reports Hy26 Results and Strategic Reset

THOMSON REUTERS

Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative

Simply Wall St.

BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million

BRIEF-Imricor Medical Systems Net Loss For Year $25.3 Million

BRIEF-Imugene Posts HY Net Loss Attributable A$37.8 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":592.0187,"timestamp":1772082000030,"preClose":587.20605,"halted":0,"volume":60428826,"delay":0,"changeRate":0.008196,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":4.812622,"latestTime":"02-26 16:00:00 AEDT","open":587.85254,"high":594.78766,"low":587.85254,"amount":151640467,"amplitude":0.01181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772146800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1772060400000,1772082000000]],"turnoverRate":0.002321,"increases":13,"decrements":16,"flats":15,"marketCap":81381771467.25,"floatMarketCap":78301869793},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":594.78766,"amplitude":0.01181,"preClose":587.20605,"low":587.85254,"latestPrice":592.0187,"volume":60428826,"delay":0,"open":587.85254,"prevYearClose":644.3692,"prevWeekClose":619.951,"prevMonthClose":674.161,"prevQuarterClose":644.369,"fiveDayClose":622.447,"twentyDayClose":665.448,"sixtyDayClose":683.947,"secType":"PLATE","market":"AU","turnoverRate":0.002321,"marketCap":81381771467.25,"floatMarketCap":78301869793,"timestamp":1772082000030,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":14,"down":17,"flat":14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614060270","title":"Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614060270","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614060270?lang=en_us&edition=fundamental","pubTime":"2026-02-26 12:03","pubTimestamp":1772078605,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its US partner Acadia Pharmaceuticals reported fourth-quarter 2025 Daybue net sales of $110 million, up 13% from a year earlier, according to a Thursday Australian bourse filing.Daybue, or trofinetide, is the company's oral Rett syndrome drug approved by the US Food and Drug Administration, Health Canada, and the Ministry of Health in Israel. The company granted Acadia an exclusive worldwide license to develop and commercialize trofinetide.Acadia expects 2026 Daybue net sales of $460 million to $490 million, implying royalty income to Neuren of AU$70 million to AU$77 million, per the filing.Neuren Pharmaceuticals' shares rose past 6% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2614205062","title":"Clinuvel H1 net profit after tax AUD 10.4 million -26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614205062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614205062?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:04","pubTimestamp":1772075090,"startTime":"0","endTime":"0","summary":"Clinuvel reported record December-half sales revenues of AUD 36.9 million in the six months to 31 December 2025 (+4%), with total revenue of AUD 40.6 million. Expenses rose to AUD 26.0 million , and net profit after tax fell to AUD 10.4 million , with basic earnings per share of AUD 0.21 . Cash and term deposits increased to AUD 233.0 million (+4%), and the balance sheet remained free of external borrowings. The company said higher spending reflected expansion plans and increased R&D activity, with personnel costs up 16% and clinical and non-clinical development costs up 19%. Commercial distribution expenses rose 42%, and finance and legal expenses increased 47%, primarily linked to an application to the U.S. SEC to upgrade its Level I ADRs to Level II for a NASDAQ listing. Management also highlighted preparation for larger markets in vitiligo and first entry to market for NEURACTHEL, an ACTH analogue.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL1H6Ww2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2614590069","title":"BRIEF-Dimerix Loss For Half-Year Attributable A$16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614590069","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614590069?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:24","pubTimestamp":1772069076,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Loss For Half-Year Attributable A$16 MillionFeb 26 (Reuters) - Dimerix Ltd DXB.AX:LOSS FOR HALF-YEAR ATTRIBUTABLE A$16 MILLIONHY REVENUES FROM ORDINARY ACTIVITIES A$2.3 MILLIONFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZL1ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2614069376","title":"BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614069376","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614069376?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:23","pubTimestamp":1772068995,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 MillionFeb 26 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:HY  NET PROFIT AFTER TAX A$10.4 MILLIONHY  REVENUES A$36.9 MILLIONFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZL25Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2614050890","title":"Clinuvel Pharmaceuticals Ltd - Hy  Revenues a$36.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050890?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:56","pubTimestamp":1772060177,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL25Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2614526057","title":"Dimerix Ltd -  Loss for Half-Year Attributable a$16 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614526057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614526057?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:31","pubTimestamp":1772058707,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7508","BK7067","BK7501"],"gpt_icon":0},{"id":"2614405216","title":"Monash IVF Group H1 Adjusted EBIT AUD 17.478 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614405216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614405216?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:15","pubTimestamp":1772057728,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLX8103D3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7113","MVF.AU","BK7508"],"gpt_icon":0},{"id":"2614052193","title":"Monash IVF Group H1 Adjusted Ebitda AUD 30.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614052193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614052193?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:15","pubTimestamp":1772057728,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLX8103D3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7113","MVF.AU","BK7508"],"gpt_icon":0},{"id":"2614052149","title":"Monash IVF Group Ltd - Expecting FY26 Underlying Group Npat of a$20 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614052149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614052149?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:15","pubTimestamp":1772057728,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLX8103D3:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7113","MVF.AU"],"gpt_icon":0},{"id":"2614405399","title":"Did Soft Half-Year Results and CEO Transition Just Shift CSL's (ASX:CSL) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614405399","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614405399?lang=en_us&edition=fundamental","pubTime":"2026-02-26 01:59","pubTimestamp":1772042374,"startTime":"0","endTime":"0","summary":"CSL’s half-year results and ongoing CEO transition, reported prior to today, disappointed parts of the market and raised questions about the company’s near-term execution and leadership stability.\nAt the same time, smaller rival Telix Pharmaceuticals drew attention with very large revenue growth and progress on a differentiated brain cancer imaging agent in Europe, sharpening comparisons within the biopharma sector.\nWe’ll now examine how concerns around CSL’s CEO transition may influence the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/did-soft-half-year-results-and-ceo-transition-just-shift-csl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/did-soft-half-year-results-and-ceo-transition-just-shift-csl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","CSL","BK4086","BK7511","SG9999004303.SGD","SGXZ23171101.USD","LU1169589451.USD","LU1169590202.USD","BK7508","BK7067","LU0728928796.USD","CSL.AU"],"gpt_icon":0},{"id":"2614399930","title":"Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2614399930","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614399930?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:40","pubTimestamp":1772034048,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were retreating Wednesday morning, edging 0.3% lower to 2,981.58 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by computer hardware maker Canaan  and travel company Tuniu , which climbed 6.5% and 5.3% respectively. They were followed by semiconductor company Silicon Motion Technology  and live video-streaming service DouYu International , which advanced 4% and 3.9% respectively.The decliners from North Asia were led by online game developer The9  and streaming music service Tencent Music Entertainment Group , which fell 3.6% and 3.5% respectively. They were followed by fintech firm LexinFintech  and brand platform Baozun , which were down 3.3% and 2.2% respectively.From South Asia, the gainers were led by IT firm Infosys , which was 1.6% higher, followed by telecommunications operator Telekomunikasi Indonesia  and lender ICICI Bank , which were up 0.9% and 0.8% respectively.The decliners from South Asi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","IE0034224299.USD","LU2087589342.USD","LU0287143357.SGD","LU0307460401.USD","BK4220","BK4107","BK4142","BK4523","LU0345776255.USD","LU0261950470.USD","LU1861217088.USD","LU1267930656.SGD","BK4554","IE00BYTNYN87.SGD","BK4596","LU2039709279.SGD","SG9999004360.SGD","LU0274383776.USD","LU0868486357.SGD","BK4115","IE0031814969.USD","BK4579","LU0264410563.USD","LU0348744763.USD","LU2008162690.USD","BK4502","BK4533","BK4108","LU0456842615.SGD","LU0737861269.HKD","LU0516423091.SGD","BK7508","BK4600","LU0441851309.USD","SIMO","LU0248272758.USD","LU2663582299.SGD","LU1323998911.USD","LU0431992006.USD","09991","BK4509","LU1366334651.USD","DOYU","LU1235295612.USD","LU1868837565.USD","IE00B0JY6M65.USD","TME","LU0289960550.SGD","BK4526","BK4207","SE","LU2125910500.SGD","BK4089","IBN","LU2177674079.SGD","LU2543165471.USD","SIFY","LU0572939691.SGD","BK7096","LU2089985449.USD","BK4531","LU0048575426.USD","LU0251143029.SGD","BK4007","IE00BYQNZ168.SGD","LU0532188223.SGD","LU0359201612.USD","SG9999001135.SGD","LU0979878070.USD","LU0541502299.USD","LU1048596156.SGD","LU0890818403.SGD","BK4532","SG9999004220.SGD","SG9999002604.SGD","LU0143863198.USD","BK4166","BK4585","LU0197229882.USD","LU0269904917.USD","LU0589944569.HKD","SG9999005177.SGD","BK4551","LU0516422366.SGD","LU0828238088.HKD","LU2360107671.USD","IE0001KFT4U8.USD","LU0048573645.USD","BK4170","LU2045819591.USD","BK7502","LU0516423174.USD","LU1023057109.AUD","LU1102505929.USD","NCTY","BK4141","IE00B3M56506.USD","LU2238330802.EUR","LU1868838027.USD","LU2065170008.USD","LU0264606111.USD","LU1366334578.USD","SG9999013478.USD","BK4563","BK4571","BK4085","LU0175139822.USD","LU1242518857.USD","LU1805238398.USD","LU1839390173.USD","SG9999002620.SGD","IE00BD6J9T35.USD","LU1242518931.SGD","BK4134","LU0251143458.SGD","LU1508157978.USD","BK4023","LU2125910849.SGD","BK4548","LU0231203729.USD","LU1048588211.SGD","BK4552","CAN","LU2065171402.SGD","01698","BK4565","SG9999002414.USD","LU0210637038.USD","BK4558","LU0823038988.USD","LU2065171311.SGD","LU0821914370.USD","BK4581","BK7016","LU0516422440.USD","SG9999002679.SGD","SG9999013460.SGD","SG9999014484.SGD","LU0828237940.HKD","LU1868837722.USD","LU0261945553.USD","BK4503","IE00B7N09G41.SGD","LU0862451753.SGD","BK4122","LU0536402901.SGD","LU0541501648.USD","LU0572940350.SGD","LU0359202008.SGD","SG9999014492.USD","LU0345775950.USD","LU0348788117.USD","LU1770036033.HKD","LU0898667661.SGD","SG9999002406.SGD","LU0791591158.USD","BZUN","LU0708995666.HKD","LU0143863784.USD","LU2065169927.USD","LU2152927971.USD","SG9999013486.USD","LU0072462343.USD","LU0791590937.USD","BK4595","LU0164881194.USD","LU2265009873.SGD","LU1481012133.USD","RDY","TLK","BK4513","LU0509642566.USD","LU1861220207.SGD","LU0181495838.USD","BK4577","BK4557","LU0499858438.USD","BK4535","LU1046422090.SGD","SG9999011746.SGD","LU0066902890.USD","LU0831103253.SGD","TOUR","LU1804176565.USD","LX","BK4117","LU0049112450.USD","LU0823039010.USD","LU0333810181.USD","BK4588","LU0531971678.HKD","IE00B12V2V27.USD","IE00BYTNYM70.SGD","INFY","SGXZ58947870.SGD","LU1102505762.USD","BK7095","LU0499858602.USD","SG9999006266.SGD","LU0516422952.EUR"],"gpt_icon":1},{"id":"1123483661","title":"Optical Communication Stocks Jump. Lumentum Soars Nearly 10%; Coherent up 8%; Lumen Technologies up over 7%; Fabrinet up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123483661","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123483661?lang=en_us&edition=fundamental","pubTime":"2026-02-25 22:55","pubTimestamp":1772031307,"startTime":"0","endTime":"0","summary":"Optical communication stocks jumped. $Lumentum(LITE)$ rose nearly 10%; $Coherent(COHR)$ rose over 8%; $Lumen Technologies(LUMN)$ rose over 7%; $Fabrinet(FN)$ rose nearly 6%; $Corning(GLW)$ up over 3%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2272731865.HKD","LU1861215975.USD","SGXZ81514606.USD","LU2473716301.USD","LU0289739343.SGD","BK4020","IE00B19Z4B17.USD","IE00BFMHRM44.USD","SGXZ99366536.SGD","LU0511384066.AUD","BK4148","LU2045819591.USD","BK4512","IE00B66KJ199.SGD","LU2089985449.USD","FN","LU0012050646.USD","LU0289961442.SGD","LU2360107168.USD","LU0240878834.USD","LU2272731600.USD","BK4554","BK7508","LU2322448791.USD","LU1861220033.SGD","LU1992135472.HKD","COHR","BK4157","BK4585","IE00B7SZL793.SGD","LITE","LU0240877869.USD","SGXZ51526630.SGD","LU0149725797.USD","LU0205194284.USD","LU1992135399.USD","LU2322448957.HKD","BK7067","BK4145","IE0031619046.USD","LU0106261612.USD","LU2211815571.USD","BK4535","LU0274383776.USD","LUMN","LITX","LU2125910500.SGD","BK4089","LU0348723411.USD","GLW","LU0205193047.USD","LU2931357623.SGD","LU2290526834.HKD","LU2272731782.SGD"],"gpt_icon":0},{"id":"2614086837","title":"BRIEF-Immuron Reports Hy26 Results And Strategic Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086837","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086837?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:26","pubTimestamp":1772018793,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Reports Hy26 Results And Strategic ResetFeb 25 (Reuters) - Immuron Ltd IMC.AX:IMMURON REPORTS HY26 RESULTS AND STRATEGIC RESETIMMURON LTD:  TAKEN A STRATEGIC DECISION TO PURSUE PARTNERSH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA6B7JXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2614856530","title":"Mesoblast Ltd  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856530","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856530?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:10","pubTimestamp":1772017813,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  expected to post a loss of7cents a share - Earnings Preview Mesoblast Ltd MESO.OQ, MESO.O is expected to  report resultson February 27 for the period ending September 30 2025The Melbour","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL8N3ZL106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7501","MSB.AU","BK7508","BK4139","BK7067"],"gpt_icon":0},{"id":"2614823085","title":"Immuron Ltd:  Taken a Strategic Decision to Pursue Partnerships to Fund Progress of Travelan and Imm-529 Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2614823085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614823085?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:00","pubTimestamp":1772017201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA6B7JXK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2614083215","title":"Immuron Reports Hy26 Results and Strategic Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614083215?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:00","pubTimestamp":1772017201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA6B7JXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2614208192","title":"Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2614208192","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614208192?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:21","pubTimestamp":1772007687,"startTime":"0","endTime":"0","summary":"Orthocell H1 2026 Earnings Snapshot\nOrthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2 million. The company’s revenue moved from A$3.6 million in H1 2025 to A$5.1 million in H2 2025 and A$5.4 million in H1 2026. Over the same periods, basic EPS shifted from a loss of A$0.006 in H1 2025 to A$0.031541 in H2 2025 and A$0.021 in H1 2026. For investors, the latest results keep the focus on how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["OCC.AU","BK7508","BK4112","BK7067","BLSG","BLSX"],"gpt_icon":0},{"id":"2614200787","title":"BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614200787","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614200787?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:43","pubTimestamp":1771983828,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 MillionFeb 25 (Reuters) - Immutep Ltd IMM.AX:HY TOTAL REVENUE AND OTHER INCOME A$7.7 MILLIONHY NET LOSS ATTRIBUTABLE A$44.9 MILLIONFurther company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2614720446","title":"BRIEF-Imricor Medical Systems Net Loss For Year $25.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614720446","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614720446?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:38","pubTimestamp":1771983533,"startTime":"0","endTime":"0","summary":"BRIEF-Imricor Medical Systems Net Loss For Year $25.3 MillionFeb 25 (Reuters) - Imricor Medical Systems Inc IMR.AX:NET LOSS FOR YEAR $25.3 MILLIONTOTAL REVENUE FOR YEAR WAS $292,309Further company coverage: IMR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK19F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK7508","IMR.AU","BK7007"],"gpt_icon":0},{"id":"2614720448","title":"BRIEF-Imugene Posts HY Net Loss Attributable A$37.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614720448","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614720448?lang=en_us&edition=fundamental","pubTime":"2026-02-25 09:38","pubTimestamp":1771983489,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Posts HY Net Loss Attributable A$37.8 MillionFeb 25 (Reuters) - Imugene Ltd IMU.AX:HY NET LOSS ATTRIBUTABLE A$37.8 MILLIONFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZK1AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":87,"code":"91000000","status":"200"}]}}